Chimeric HP-PRRSV2 containing an ORF2-6 consensus sequence induces antibodies with broadly neutralizing activity and confers cross protection against virulent NADC30-like isolate

Table 2 Virus neutralization properties of sera with distinct neutralization activities.

PRRSV subgroups	Representative isolates	Mock inoculation	TJM-F92 inoculation	rJS-ORF2-6-CON inoculation
PRRSV subgroups	Representative isolates	Pig 3	Pig 6	Pig 12
JXA1-like HP-PRRSV2	JSTZ1712-12 (MK906026) (99/92)^a	< 8^b	64	32
JXA1-like HP-PRRSV2	JXA1-R (MT163314) (99/91)	< 8	32	16
CH-1a-like PRRSV2	SD1612-1 (MN119304) (96/93)	< 8	< 8	32
CH-1a-like PRRSV2	CH-1R (EU807840) (96/93)	< 8	< 8	16
VR-2332-like PRRSV2	JSYC20-05-1 (MT746146) (92/94)	< 8	< 8	16
VR-2332-like PRRSV2	R98 (DQ355796) (92/94)	< 8	< 8	16
NADC30-like PRRSV2	SD17-36 (MH121061) (86/90)	< 8	< 8	8
NADC30-like PRRSV2	SD17-38 (MH068878) (85/90)	< 8	< 8	16
NADC34-like PRRSV2	Anheal-1 (MH370474) (86/90)	< 8	< 8	8
PRRSV1	HLJB1 (KT224385) (61/65)	< 8	< 8	8

^aThe numbers indicate the nucleotide identities between ORF2-6 sequences of TJM-F92 vaccine/chimeric virus (rJS-ORF2-6-CON) and ORF2-6 from representative PRRSV isolates, respectively.
^bThe neutralization titer shows an inverse of the highest serum dilution with virus neutralization activity. Titer < 8 indicates no detectable virus neutralization activity.

ISSN: 1297-9716